Continuous administration of the 5-hydroxytryptamine1A agonist (3-chloro-4-fluoro-phenyl)-[4-fluoro-4-{[(5-methyl-pyridin-2-ylmethyl)-amino]-methyl}piperidin-1-yl]-methadone (F 13640) attenuates allodynia-like behavior in a rat model of trigeminal neuropathic pain

被引:40
|
作者
Deseure, K
Koek, W
Adriaensen, H
Colpaert, FC
机构
[1] Univ Antwerp, Lab Anesthesiol, B-2020 Antwerp, Belgium
[2] Ctr Rech Pierre Fabre, F-81106 Castres, France
来源
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS | 2003年 / 306卷 / 02期
关键词
D O I
10.1124/jpet.103.050286
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
(3-Chloro-4-fluoro-phenyl)-[4-fluoro-4-{[(5-methyl-pyridin-2-yl-methyl)amino]-methyl}piperidin-1-yl]-methadone (F 13640) is a recently discovered high-efficacy 5-hydroxytryptamine (HT)(1A) receptor agonist that produces central analgesia through the neuroadaptive mechanisms of inverse tolerance and cooperation. In a rat model of trigeminal neuropathic pain, the chronic constriction injury of the infraorbital nerve causes allodynia-like behavior that develops within 2 weeks and remains stable thereafter. We report that early after surgery, during which time allodynia develops, the continuous 2-week infusion of 0.63 mg/day F 13640 inhibited the allodynia-like behavior, whereas 5 mg/day morphine showed no significant effect. When F 13640 infusion was initiated late after surgery, when allodynia was well established, it produced an antiallodynic effect that was apparent during the entire infusion period. In contrast, morphine infusion caused an initially marked antiallodynic effect to which tolerance developed within the 2-week infusion period. The GABA-B receptor agonist baclofen (1.06 mg/day) that has a recognized usefulness in the treatment of trigeminal neuralgia, demonstrated effectiveness in both conditions. The data are consistent with a theory of nociceptive signal transduction, as well as with previous data, in demonstrating the neuroadaptive mechanisms of inverse tolerance and cooperation. That is, in contrast with morphine, the antiallodynic effect induced by 5-HT1A receptor activation does not decay, but, if anything, grows with chronicity. Also, 5-HT1A receptor activation seemed to cooperate with nociceptive stimulation in, paradoxically, inducing an antiallodynic effect. The data presented here suggest that F 13640 may perhaps offer a lasting treatment of trigeminal neuralgia.
引用
收藏
页码:505 / 514
页数:10
相关论文
共 22 条
  • [1] Dual, hyperalgesic, and analgesic effects of the high-efficacy 5-hydroxytryptamine 1A (5-HT1A) agonist F 13640 [(3-chloro-4-fluoro-phenyl)-[4-fluoro-4-{[(5-methyl-pyridin-2-ylmethyl)-amino]-methyl}piperidin-1-yl]methanone, fumaric acid salt]:: Relationship with 5-HT1A receptor occupancy and kinetic parameters
    Bardin, L
    Assié, MB
    Pélissou, M
    Royer-Urios, I
    Newman-Tancredi, A
    Ribet, JP
    Sautel, F
    Koek, W
    Colpaert, FC
    JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2005, 312 (03): : 1034 - 1042
  • [2] ADX47273 [S-(4-Fluoro-phenyl)-{3-[3-(4-fluoro-phenyl)-[1,2,4]-oxadiazol-5-yl]-piperidin-1-yl}-methanone]: A Novel Metabotropic Glutamate Receptor 5-Selective Positive Allosteric Modulator with Preclinical Antipsychotic-Like and Procognitive Activities
    Liu, Feng
    Grauer, Steve
    Kelley, Cody
    Navarra, Rachel
    Graf, Radka
    Zhang, Guoming
    Atkinson, Peter J.
    Popiolek, Michael
    Wantuch, Caitlin
    Khawaja, Xavier
    Smith, Deborah
    Olsen, Michael
    Kouranova, Evguenia
    Lai, Margaret
    Pruthi, Farhana
    Pulicicchio, Claudine
    Day, Mark
    Gilbert, Adam
    Pausch, Mark H.
    Brandon, Nicholas J.
    Beyer, Chad E.
    Comery, Tom A.
    Logue, Sheree
    Rosenzweig-Lipson, Sharon
    Marquis, Karen L.
    JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2008, 327 (03): : 827 - 839
  • [3] SAR studies in the identification of 2-chloro-4-fluoro-N-[6-(1-methyl-piperidine-4-carbonyl)-pyridin-2-yl]-benzamide as a potent and selective 5-HT1F receptor.
    Xu, YC
    Kohlman, DT
    Liang, SX
    Ying, BP
    Cohen, MP
    Zacherl, DP
    Benesh, DR
    Blanco, MJ
    Filla, SA
    Hudziak, KJ
    Mathes, BM
    Victor, F
    Zhang, D
    Chen, Q
    Gough, WH
    Nelson, DL
    Mutter, SE
    Wainscott, DB
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2004, 227 : U55 - U55
  • [4] A stereoselective synthesis of (S)-2-(((3-fluoro-4-methylphenoxy)carbonyl)(1-(4-((5-methyl-2-phenyloxazol-4-yl)methoxy)phenyl)ethyl)amino)acetic acid, a highly potent PPAR α/γ dual agonist
    Qian, Xinhua
    Tang, Erqing
    Fan, Junying
    Zhu, Keming
    Zhu, Jinyang
    Shabaker, John
    Lo, Ehrlic
    Malley, Mary
    Deshpande, Rajendra
    TETRAHEDRON, 2015, 71 (50) : 9408 - 9414
  • [5] An efficient synthesis of 2-amino-4-(4-fluoro-3-(2-fluoropyridin-3-yl)phenyl)-4-(4-methoxy-3-methylphenyl)-1-methyl-1H-imidazol-5(4H)-one, a potent BACE1 inhibitor
    Zhou, Ping
    Malamas, Michael
    Robichaud, Albert J.
    ARKIVOC, 2010, : 84 - 88
  • [6] METABOLISM OF N-[4-CHLORO-2-FLUORO-5-[(1-METHYL-2-PROPYNYL)OXY]PHENYL]-3,4,5,6-TETRAHYDROPHTHALIMIDE (S-23121) IN THE RAT .2. ABSORPTION, DISPOSITION, EXCRETION AND BIOTRANSFORMATION
    YOSHINO, H
    KANEKO, H
    NAKATSUKA, I
    YAMADA, H
    XENOBIOTICA, 1993, 23 (10) : 1075 - 1084
  • [7] SLV313 (1-(2,3-Dihydro-Benzo[1,4]Dioxin-5-yl)-4- [5-(4-Fluoro-Phenyl)-Pyridin-3-ylmethyl]-Piperazine Monohydrochloride): A Novel Dopamine D2 Receptor Antagonist and 5-HT1A Receptor Agonist Potential Antipsychotic Drug
    Andrew C McCreary
    Jeffrey C Glennon
    Charles R Ashby
    Herbert Y Meltzer
    Zhu Li
    Jan-Hendrik Reinders
    Mayke B Hesselink
    Stephen K Long
    Arnoud H Herremans
    Herman van Stuivenberg
    Rolf W Feenstra
    Chris G Kruse
    Neuropsychopharmacology, 2007, 32 : 78 - 94
  • [8] SLV313 (1-(2,3-dihydro-benzo[1,4]dioxin-5-yl)-4-[5-(4-fluoro-phenyl)-pyridin-3-ylmethyl]-piperazine monohydrochloride):: A novel dopamine D2 receptor antagonist and 5-HT1A receptor agonist potential antipsychotic drug
    McCreary, Andrew C.
    Glennon, Jeffrey C.
    Ashby, Charles R., Jr.
    Meltzer, Herbert Y.
    Li, Zhu
    Reinders, Jan-Hendrik
    Hesselink, Mayke B.
    Long, Stephen K.
    Herremans, Arnoud H.
    van Stuivenberg, Herman
    Feenstra, Rolf W.
    Kruse, Chris G.
    NEUROPSYCHOPHARMACOLOGY, 2007, 32 (01) : 78 - 94
  • [9] METABOLISM OF N-[4-CHLORO-2-FLUORO-5-[(1-METHYL-2-PROPYNYL)OXY]PHENYL]-3,4,5,6-TETRAHYDROPHTHALIMIDE (S-23121) IN THE RAT .1. IDENTIFICATION OF A NEW, SULFONIC-ACID TYPE OF CONJUGATE
    YOSHINO, H
    MATSUNAGA, H
    KANEKO, H
    YOSHITAKE, A
    NAKATSUKA, I
    YAMADA, H
    XENOBIOTICA, 1993, 23 (06) : 609 - 619
  • [10] Discovery of a Teraryl Oxazolidinone Compound (S)-N-((3-(3-Fluoro-4-(4-(pyridin-2-yl)-1H-pyrazol-1-yl)phenyl)-2-oxooxazolidin-5-yl)-methyl)acetamide Phosphate as a Novel Antimicrobial Agent with Enhanced Safety Profile and Efficacies
    Yang, Tao
    Chen, Gong
    Sang, Zitai
    Liu, Yuanyuan
    Yang, Xiaoyan
    Chang, Ying
    Long, Haiyue
    Ang, Wei
    Tang, Jianying
    Wang, Zhenling
    Li, Guobo
    Yang, Shengyong
    Zhang, Jingren
    Wei, Yuquan
    Luo, Youfu
    JOURNAL OF MEDICINAL CHEMISTRY, 2015, 58 (16) : 6389 - 6409